Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval

Introduction: Trastuzumab has become the standard treatment for both HER2-positive early and metastatic breast cancer (HER2+ eBC or mBC) since its approval. The objective of the study is to estimate the benefit of adjuvant trastuzumab in the treatment of patients with HER2+ eBC in terms of life year...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciruelos, Eva, Alba, Emilio, López, Rafael, Lluch, Anna, Martín, Miguel, Arroyo, Isabel, Navarro, Beatriz, Carcedo, David, Colomer, Ramón, Albanell, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611514/
https://www.ncbi.nlm.nih.gov/pubmed/31303965
http://dx.doi.org/10.18632/oncotarget.27039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611514/
https://www.ncbi.nlm.nih.gov/pubmed/31303965
http://dx.doi.org/10.18632/oncotarget.27039

Ejemplares similares